目的分析肺癌肿瘤抑制因子1(tumor suppressor in lung cancer 1,TSLC1)与乳腺癌临床病理和预后关系。方法收集女性乳腺癌组织125例,采用免疫组织化学技术检测TSLC1表达。结果 TSLC1主要表达在乳腺癌细胞质,其阳性率为38.4%(48/125),与...目的分析肺癌肿瘤抑制因子1(tumor suppressor in lung cancer 1,TSLC1)与乳腺癌临床病理和预后关系。方法收集女性乳腺癌组织125例,采用免疫组织化学技术检测TSLC1表达。结果 TSLC1主要表达在乳腺癌细胞质,其阳性率为38.4%(48/125),与患者的年龄、肿瘤大小、淋巴结转移、临床分期、人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)表达无关,而与雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)表达相关(P<0.001)。ER^+(阳性)患者TSLC1阳性率低于ER-(阴性)患者[28.4%(25/88)与62.2%(23/37)];同样,PR^+患者TSLC1阳性率低于PR^-患者[24.3%(17/70)与56.4%(31/55)]。Z检验显示在ER^+PR^-的乳腺癌患者中TSLC1^-和TSLC1^+患者3年生存率差异有统计学意义(83.3%与14.3%,P=0.007),总体生存曲线差异有统计学意义(P=0.003)。Cox多因素回归分析,TSLC1不是ER^+PR^-乳腺癌患者独立的危险预后因素(比值比10.696,95%可信区间0.988~115.843,P=0.051)。结论 TSLC1在乳腺癌致病机制中与ER、PR相关,可作为临床ER^+PR^-乳腺癌患者新的预后指标。展开更多
Objective: Exploring the clinical signification of high-mobility group box 1 protein(HMGB1) expression in infiltrating ductal carcinoma(IDC) breast tissue. Methods: The expression of HMGB1 protein in IDC breast tissue...Objective: Exploring the clinical signification of high-mobility group box 1 protein(HMGB1) expression in infiltrating ductal carcinoma(IDC) breast tissue. Methods: The expression of HMGB1 protein in IDC breast tissue was detected by immunohistochemistry, and the relations among size of tumour, lymph node metastasis, clinical staging, estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor receptor 2(HER-2) were also analyzed. Results: Fortysix cases out of 60 cases of IDC breast tissue showed positive or strong positive HMGB1 expression(76.67%), statistical significance was observed between HMGB1 expression with clinical staging(P < 0.01), lymph node metastasis(P < 0.01), breast cancer ER(P < 0.05) and HER-2(P < 0.05), however same conclusion can not be drawn between HMGB1 with either size of tumour or PR expression(P > 0.05) in IDC breast tissue. Spearman analysis showed negative correlation between HMGB1 expression and ER, and positive correlation between HMGB1 expression and clinical staging, lymph node metastasis together with HER-2. Conclusion: It's promising that HMGB1 expression in IDC tissue can be one of biological indicators of poor prognosis.展开更多
Estrogen and estrogen receptor-alpha(ER)signaling are important factors in the pathogenesis and treatment of ER-positive breast cancers.Therefore targeted therapies against ER,known as endocrine therapies,are widely u...Estrogen and estrogen receptor-alpha(ER)signaling are important factors in the pathogenesis and treatment of ER-positive breast cancers.Therefore targeted therapies against ER,known as endocrine therapies,are widely used in the treatment of ER-positive breast cancers.While these therapies have shown great success,de novo and acquired resistance are common.The approach to the problem of endocrine therapy resistance is twofold:identify the mechanisms of resistance and develop alternative treatments to overcome these mechanisms.This review focuses on the progress and integration of these two aspects of resolving endocrine therapy resistance in ER-positive breast cancer patients.展开更多
基金Supported by a grant from the Innovation Foundation of Excellent Intellectuals in Henan Province(No.2109901)
文摘Objective: Exploring the clinical signification of high-mobility group box 1 protein(HMGB1) expression in infiltrating ductal carcinoma(IDC) breast tissue. Methods: The expression of HMGB1 protein in IDC breast tissue was detected by immunohistochemistry, and the relations among size of tumour, lymph node metastasis, clinical staging, estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor receptor 2(HER-2) were also analyzed. Results: Fortysix cases out of 60 cases of IDC breast tissue showed positive or strong positive HMGB1 expression(76.67%), statistical significance was observed between HMGB1 expression with clinical staging(P < 0.01), lymph node metastasis(P < 0.01), breast cancer ER(P < 0.05) and HER-2(P < 0.05), however same conclusion can not be drawn between HMGB1 with either size of tumour or PR expression(P > 0.05) in IDC breast tissue. Spearman analysis showed negative correlation between HMGB1 expression and ER, and positive correlation between HMGB1 expression and clinical staging, lymph node metastasis together with HER-2. Conclusion: It's promising that HMGB1 expression in IDC tissue can be one of biological indicators of poor prognosis.
基金This work was supported by:The Avon Foundation(BHP)and the Canney Foundation.We would also like to thank and acknowledge the support of National Institutes of Health P30 CA006973the Sandy Garcia Charitable Foundation,the Commonwealth Foundation,the Santa Fe Foundation,the Marcie Ellen Foundation,The Helen Golde Trust and The Robin Page/Lebor Foundation.
文摘Estrogen and estrogen receptor-alpha(ER)signaling are important factors in the pathogenesis and treatment of ER-positive breast cancers.Therefore targeted therapies against ER,known as endocrine therapies,are widely used in the treatment of ER-positive breast cancers.While these therapies have shown great success,de novo and acquired resistance are common.The approach to the problem of endocrine therapy resistance is twofold:identify the mechanisms of resistance and develop alternative treatments to overcome these mechanisms.This review focuses on the progress and integration of these two aspects of resolving endocrine therapy resistance in ER-positive breast cancer patients.